CHRS — Coherus Oncology, Inc.

Coherus Oncology Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: LOQTORZI net revenue reached $11.2 million, marking a 12% increase quarter-over-quarter and a 92% increase year-over-year. However, this growth rate declined from 35% in Q2 2025.
• Expenses: R&D expenses increased to $27.3 million (up 24% YoY), reflecting investments in the pipeline. SG&A expenses decreased to $24.9 million (down 11% YoY) due to reduced headcount following the exit from the biosimilar business.
• Balance Sheet: Cash and investments totaled $192 million, with total liabilities at $429 million, of which $254 million pertained to transition service agreements. The company has significantly improved its balance sheet compared to the previous year.

2. Strategic Updates and Business Highlights

• Leadership Changes: Arvind Sood was appointed as Chief Strategy and Corporate Affairs Officer.
• Product Development: LOQTORZI is being combined with proprietary assets and other therapies to enhance patient survival. The company is pursuing clinical trials in liver, lung, head and neck, gastric, esophageal, and colorectal cancers.
• Pipeline Progress: Enrollment in clinical trials for CHS-114 and casdozokitug is progressing well, with data expected in 2026.
• Market Dynamics: The company is expanding its sales force by 15% and enhancing multichannel capabilities to increase awareness and adoption of LOQTORZI in community settings.

3. Forward Guidance and Outlook

• Revenue Growth: Coherus anticipates achieving a dominant share in the nasopharyngeal cancer market, estimating a long-term demand growth of 10% to 15% annually over the next three years.
• Clinical Data: Key data readouts from multiple studies are expected in 2026, which may drive future partnerships and revenue opportunities.

4. Bad News, Challenges, or Points of Concern

• Declining Growth Rate: The growth rate of LOQTORZI sales has slowed compared to previous quarters, raising concerns about sustaining momentum.
• Sales Force Challenges: One sales region experienced flat growth due to staffing issues, which the company is addressing.
• Competitive Pressures: The company faces challenges in educating community physicians about LOQTORZI, as awareness remains low compared to hospital-based specialists.

5. Notable Q&A Insights

• Combination Therapies: There was interest in exploring bispecific therapies targeting CCR8 and PD-1, but the management suggested traditional combination therapies might yield stronger clinical responses.
• Colorectal Cancer Benchmarks: The fourth-line colorectal cancer population has a low overall response rate (~5-6%). The company aims to exceed these benchmarks with CHS-114.
• Duration of Therapy: The average duration of therapy for LOQTORZI is increasing, but the company has not yet reached the average seen in clinical trials.
• Data Expectations: For casdozokitug, the company is looking for solid overall response rates and durability in upcoming Phase II data to justify moving to pivotal studies.

Overall, Coherus Oncology is making strides in its strategic initiatives and pipeline development while facing challenges in sustaining revenue growth and educating the market. The upcoming data readouts in 2026 are critical for the company's future trajectory.